Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies

Clinical Lung Cancer

Volumn 14, Issue 5, 2013, Pages 581-591

  Bauml, Joshua ^a   Mick, Rosemarie ^b   Zhang, Yu ^a   Watt, Christopher D ^a   Vachani, Anil ^a   Aggarwal, Charu ^a   Evans, Tracey ^a   Langer, Corey ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EGFR; KRAS; Non small cell lung cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BODY WEIGHT; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; GENDER; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SKIN METASTASIS; SMOKING; SURVIVAL TIME; SYSTEMIC THERAPY;

EGFR; KRAS; NON-SMALL-CELL LUNG CANCER; PROGNOSIS;

ADENOCARCINOMA; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883786873     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.05.002     Document Type: Article

References (45)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. M. Fukuoka, Y.-L. Wu, and S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
3. C. Zhou, Y.-L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
4. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
5. E.L. Kwak, Y.-J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
6. K. Bergethon, A.T. Shaw, and S.-H.I. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
7. S.P. D'Angelo, M.C. Pietanza, and M.L. Johnson Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas J Clin Oncol 29 2011 2066 2070
8. A. Marchetti, C. Martella, and L. Felicioni EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
9. H. Sasaki, S. Shimizu, and K. Endo EGFR and erbB2 mutation status in Japanese lung cancer patients Int J Cancer 118 2006 180 184
10. M. de Perrot, M. Licker, and C. Bouchardy Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma J Thorac Cardiovasc Surg 119 2000 21 26
11. J. Moldvay, P. Scheid, and P. Wild Predictive survival markers in patients with surgically resected non-small cell lung carcinoma Clin Cancer Res 6 2000 1125 1134
12. P. Sardari Nia, J. Weyler, and C. Colpaert Prognostic value of smoking status in operated non-small cell lung cancer Lung Cancer 47 2005 351 359
13. S. Rodenhuis, and R.J. Slebos Clinical significance of ras oncogene activation in human lung cancer Cancer Res 52 9 Suppl 1992 2665s 2669s
14. J.F. Piccirillo, R.M. Tierney, and I. Costas Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older JAMA 285 2001 2441 2447
15. J.F. Piccirillo, R.M. Tierney, and I. Costas Prognostic importance of comorbidity in a hospital-based cancer registry JAMA 291 2004 2441 2447
16. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 1987 373 383
17. D.L. Aisner, C. Deshpande, and Z. Baloch Evaluation of EGFR mutation status in cytology specimens: an institutional experience Diagn Cytopathol 41 2013 316 323
18. L.V. Sequist, V.A. Joshi, and P.A. Jänne Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing Oncologist 12 2007 90 98
19. M.L. Johnson, C.S. Sima, and J. Chaft Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas Cancer 119 2013 356 362
20. M. Tokumo, S. Toyooka, and K. Kiura The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 2005 1167 1173
21. T. Kosaka, Y. Yatabe, and H. Endoh Mutations of the epidermal growth factor receptor gene in lung cancer Cancer Res 64 2004 8919 8923
22. H. Shigematsu, L. Lin, and T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
23. J.L. Marks, S. Broderick, and Q. Zhou Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
24. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
25. Y. Fukuyama, T. Mitsudomi, and K. Sugio K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer Br J Cancer 75 1997 1125 1130
26. C.L. Huang, T. Taki, and M. Adachi Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer Int J Oncol 12 1998 553 563
27. H.H. Nelson, D.C. Christiani, and E.J. Mark Implications and prognostic value of K-ras mutation for early-stage lung cancer in women J Natl Cancer Inst 91 1999 2032 2038
28. P.M. Schneider, H.W. Praeuer, and O. Stoeltzing Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer Br J Cancer 83 2000 473 479
29. S. Rodenhuis, L. Boerrigter, and B. Top Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study J Clin Oncol 15 1997 285 291
30. D.J. Kwiatkowski, D.H. Harpole, and J. Godleski Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications J Clin Oncol 16 1998 2468 2477
31. C. Mascaux, N. Iannino, and B. Martin The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
32. A.J. Nixon, D. Neuberg, and D.F. Hayes Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer J Clin Oncol 12 1994 888 894
33. C. Schoch, W. Kern, and S. Schnittger The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups Haematologica 89 2004 1082 1090
34. M. Werner-Wasik, C. Scott, and J.D. Cox Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival Int J Radiat Oncol Biol Phys 48 2000 1475 1482
35. M. Fruh, E. Rolland, and J.P. Pignon Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer J Clin Oncol 26 2008 3573 3581
36. C. Langer, C. Hsu, and W. Curran Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10 Int J Radiat Oncol Biol Phys 51 2001 20 21
37. T. Maeda, H. Ueoka, and M. Tabata Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis Jpn J Clin Oncol 30 2000 534 541
38. F. Saad, A. Lipton, and R. Cook Pathologic fractures correlate with reduced survival in patients with malignant bone disease Cancer 110 2007 1860 1867
39. V.J. Lanzotti, D.R. Thomas, and L.E. Boyle Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria Cancer 39 1977 303 313
40. D.M. Finkelstein, D.S. Ettinger, and J.C. Ruckdeschel Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study J Clin Oncol 4 1986 702 709
41. J.P. O'Connell, M.G. Kris, and R.J. Gralla Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy J Clin Oncol 4 1986 1604 1614
42. S. Firat, R.W. Byhardt, and E. Gore Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 54 2002 357 364
43. G. Frasci, V. Lorusso, and N. Panza Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 18 2000 2529 2536
44. S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
45. J.P. Patel, M. Gonen, and M.E. Figueroa Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089